for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PharmAust Limited

PAA.AX

Latest Trade

0.09AUD

Change

-0.00(-1.16%)

Volume

114,488

Today's Range

0.08

 - 

0.09

52 Week Range

0.08

 - 

0.14

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.09
Open
0.09
Volume
114,488
3M AVG Volume
8.21
Today's High
0.09
Today's Low
0.08
52 Week High
0.14
52 Week Low
0.08
Shares Out (MIL)
316.73
Market Cap (MIL)
26.94
Forward P/E
--
Dividend (Yield %)
--

Next Event

Pharmaust Ltd Annual Shareholders Meeting

Latest Developments

更多

Pharmaust Achieves Interim Clinical Endpoints For Phase IIb Trial In Pet Dogs With B Cell Lymphoma

Pharmaust Receives Ethics Approval For Phase I Trial In MND

Pharmaust Receives Ethics Approvals To Commence Phase Iib Dog Cancer Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PharmAust Limited

Pharmaust Limited is an Australia-based clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for pet dogs. The Company's lead candidate, monepantel (MPL), is a small molecule drug primarily being developed as a safe and potent treatment for cancer. The MPL can also be used for neurodegenerative diseases such as Motor Neuron Disease, Parkinson's Disease, and Alzheimer's Disease. It has completed Phase I clinical trials with MPL in humans and dogs diagnosed with solid tumors. The Company has also initiated a preclinical program to screen its portfolio of aminoacetonitrile (AAD) compounds for anticancer activity.

Industry

Biotechnology & Drugs

Contact Info

Suite 116, 1 Kyle Way, Claremont

NEDLANDS, WAS

6010

Australia

+61.8.92026814

http://www.pharmaust.com/

Executive Leadership

Martine Keenan

Chief Executive Officer

Robert Charles Bishop

Executive Director

John Horton

Director of Epichem Pty Ltd

Colette G. Sims

Director of Epichem Pty Ltd

Sam Michael Wright

Company Secretary, Non-Executive Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
7.34
Price To Book (MRQ)
3.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
14.39
LT Debt To Equity (MRQ)
12.74
Return on Investment (TTM)
-13.56
Return on Equity (TTM)
-12.33

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up